| 000 | 01765 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250515182102.0 | ||
| 264 | 0 | _c20091026 | |
| 008 | 200910s 0 0 eng d | ||
| 022 | _a1471-6771 | ||
| 024 | 7 |
_a10.1093/bja/aep204 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCarpenter, D | |
| 245 | 0 | 0 |
_aGenetic variation in RYR1 and malignant hyperthermia phenotypes. _h[electronic resource] |
| 260 |
_bBritish journal of anaesthesia _cOct 2009 |
||
| 300 |
_a538-48 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAnesthetics, Inhalation _xpharmacology |
| 650 | 0 | 4 |
_aCaffeine _xpharmacology |
| 650 | 0 | 4 |
_aCreatine Kinase _xblood |
| 650 | 0 | 4 |
_aDNA Mutational Analysis _xmethods |
| 650 | 0 | 4 |
_aDNA, Complementary _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenetic Predisposition to Disease |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHalothane _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMalignant Hyperthermia _xenzymology |
| 650 | 0 | 4 |
_aMuscle Contraction _xdrug effects |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aPhosphodiesterase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aRyanodine Receptor Calcium Release Channel _xgenetics |
| 650 | 0 | 4 | _aTissue Culture Techniques |
| 700 | 1 | _aRobinson, R L | |
| 700 | 1 | _aQuinnell, R J | |
| 700 | 1 | _aRingrose, C | |
| 700 | 1 | _aHogg, M | |
| 700 | 1 | _aCasson, F | |
| 700 | 1 | _aBooms, P | |
| 700 | 1 | _aIles, D E | |
| 700 | 1 | _aHalsall, P J | |
| 700 | 1 | _aSteele, D S | |
| 700 | 1 | _aShaw, M-A | |
| 700 | 1 | _aHopkins, P M | |
| 773 | 0 |
_tBritish journal of anaesthesia _gvol. 103 _gno. 4 _gp. 538-48 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/bja/aep204 _zAvailable from publisher's website |
| 999 |
_c19055429 _d19055429 |
||